Masami Ezaki

This inventor holds 19 USPTO granted patents and 1 EPO patent, primarily in Cyclic Lipopeptide Research. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1987-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masami Ezaki. Retrieved from https://idiyas.com/inventor/masami-ezaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 89.5

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.8

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Osaka, JP (1987)
Tsukuba, JP (1990 - 2003)
Ibaraki, JP (2004)

Company Filing History:

19 out of 940

Fujisawa Pharmaceutical Company, Ltd.

patents

Years Active: 1987-2004

Loading Chart...

Areas of Expertise:

Cyclic Lipopeptide

Acylase

Deacylation

Antimicrobial Agent

WS-9326A

WS-7622A

Pharmaceutical Composition

Amino Acid Derivatives

Therapeutic Composition

Production Process

Compound Production

Peptide Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6825003 - Cyclic lipopeptide acylase (2004-11-30),

2. 6573084 - Process for the deacylation of cyclic lipopeptides (2003-06-03),

3. 6537789 - Process for the deacylation of cyclic lipopeptides (2003-03-25),

4. 6521600 - Compound, WF002, production thereof and use thereof (2003-02-18),

5. 6372474 - Cyclic lipopeptide acylase (2002-04-16),

6. 6207434 - Process for the deacylation of cyclic lipopeptides (2001-03-27),

7. 6146872 - Cyclic lipopeptide acylase (2000-11-14),

8. 5514715 - Antimicrobial agent, FR109615 and production thereof (1996-05-07),

9. 5436140 - Process for producing WS-9326A and WS-9326B (1995-07-25),

10. 5364624 - WS7622A mono- or di-sulfate, process for preparation thereof and use (1994-11-15),

11. 5292510 - WS7622A mono- or di- sulfate, process for preparation thereof and use (1994-03-08),

12. 5279826 - Prophylactic/therapeutic composition for disseminated intravascular (1994-01-18),

13. 5217952 - Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof (1993-06-08),

14. 5167958 - WS7622A, B, C and D substances, derivatives thereof, processes for (1992-12-01),

15. 5037809 - Antimicrobial agent, FR109615 and production thereof (1991-08-06),

Title: Masami Ezaki: Innovator in Cyclic Lipopeptide Research

Introduction: Masami Ezaki, an acclaimed inventor based in Tsukuba, Japan, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 19 patents, his innovations have played a pivotal role in advancing medical science and drug development.

Latest Patents: Among his most notable inventions is the "Cyclic lipopeptide acylase," which focuses on the "Process for the deacylation of cyclic lipopeptides." These inventions reflect his dedication to enhancing pharmaceutical applications and improving therapeutic outcomes.

Career Highlights: Masami Ezaki has established a successful career at Fujisawa Pharmaceutical Company, Ltd. His innovative spirit has led to the development of critical technologies that tackle complex challenges in the pharmaceutical industry. His work continues to inspire peers and contribute to advancements in drug formulation.

Collaborations: Throughout his career, Ezaki has collaborated with distinguished colleagues, including Masakuni Okuhara and Seiji Hashimoto. These partnerships have fostered a dynamic environment for innovation, resulting in groundbreaking research and development within the industry.

Conclusion: Masami Ezaki exemplifies the spirit of innovation in the pharmaceutical sector. His insights and inventions are not only advancing scientific inquiry but also paving the way for new therapies that can improve patient care and outcomes.

Profile summary based on public USPTO records.